---
title: Study of an Enhanced Lithotripsy System (ELS) in the Treatment of Urinary Stone Disease
nct_id: NCT04771182
overall_status: TERMINATED
phase: NA
sponsor: Avvio Medical
study_type: INTERVENTIONAL
primary_condition: Urinary Stone
countries: Australia
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04771182.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04771182"
ct_last_update_post_date: 2026-04-03
last_seen_at: "2026-05-12T06:56:46.285Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Study of an Enhanced Lithotripsy System (ELS) in the Treatment of Urinary Stone Disease

**NCT ID:** [NCT04771182](https://clinicaltrials.gov/study/NCT04771182)

## Key Facts

- **Status:** TERMINATED
- **Why Stopped:** Adequate enrollment has been achieved
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 25
- **Lead Sponsor:** Avvio Medical
- **Conditions:** Urinary Stone
- **Start Date:** 2019-02-08
- **Completion Date:** 2022-10-05
- **CT.gov Last Update:** 2026-04-03

## Brief Summary

This is a single arm, multi-center study to assess the safety and efficacy of a form of extracorporeally induced lithotripsy, called the Enhanced Lithotripsy System, to treat urinary stones.

## Detailed Description

This is a single arm, multi-center study to assess the safety and efficacy of a form of extracorporeally induced lithotripsy, called the Enhanced Lithotripsy System, to treat urinary stones. Subjects will be treated up to 2 times with the Enhanced Lithotripsy System and followed for 90 days after the last treatment session.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 75 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. Male or female aged ≥ 18 years
2. Provides written informed consent
3. Understands and accepts the study requirements
4. One urinary stone eligible for treatment (minimum) that is:

   1. apparent on a computed tomography (CT) scan within 14 days prior to study enrollment
   2. located within the renal pelvis or ureter
   3. is ≥ 3 mm in at least one dimension and ≤ 10 mm in maximum
   4. less than or equal to 10mm in maximum dimension and has an area less than 56mm2 as estimated by pre-procedure CT dimension as estimated by pre- procedure CT
5. Participants with two or more stones in one or both kidneys are admissible and must meet the following inclusion criteria:

   1. Number of stones (≥ 3 mm) present on treated side is 2 or less
   2. Untreated stones must not be anticipated to require treatment within 30 days of enrollment, as determined by the investigator

Exclusion Criteria:

1. Age less than 18 years of age or over 75 years of age
2. Diagnosis of radiolucent stones
3. History of cystinuria
4. Urine pH below 5.5
5. Current untreated urinary tract infection
6. Pregnancy
7. Vulnerable individuals (mentally disabled, physically disabled, prisoner, etc.)
8. Enrollment in another research study or previous participation within 30 days of enrollment.
9. Participant has planned general anesthesia during index procedure with American Society of Anesthesiologists (ASA) physical classification level of 3 or greater
10. Known sensitivity to possible medications used before, during, or after the ELS procedure, including but not limited to the following: sedative agents, general anaesthetics, topical anaesthetics, and opioid analgesics
11. Coagulation abnormality or taking prescription anticoagulants that cannot be stopped during treatment. Aspirin usage will be discontinued at least 7 days prior to enrollment at the discretion of the attending physician
12. Mobility issues - unable to comfortably lie still for up to 120 minutes or unable to roll from back to side
13. Known hypersensitivity to conductivity gel
14. Body mass index (BMI) ≥ 35 unless anticipated skin to stone distance (anticipated distance from site of ELS treatment head to stone per pre-operative CT) is \<135mm
15. Implanted spinal cord neurostimulator intrathecal pump or any device that may interfere with energy transmission
16. Participant has open wounds, lesions, dermatitis, or ischemic tissues in the treatment area
17. Participant has had a major surgery that removed tissue around the spinal cord (e.g. a laminectomy) within the treatment area
18. Participant will undergo treatment of a stone located in the distal ureter and has previous hernia repair or surgical mesh implanted in the inguinal/hypogastric regions
```

## Arms

- **Enhanced Lithotripsy System** (EXPERIMENTAL) — Treatment of urinary stone disease with the Enhanced Lithotripsy System

## Interventions

- **Enhanced Lithotripsy System** (DEVICE) — Treatment of urinary stone disease with the Enhanced Lithotripsy System

## Primary Outcomes

- **Number of Participants With Treatment Success** _(time frame: 30 days)_ — Proportion of study participants who, after up to 2 ELS treatments, have a complete absence of stones or with any residual fragments measuring less than 3 mm in the largest dimension as assessed by follow-up imaging

## Secondary Outcomes

- **Percentage of Participants With Serious Device and/or Serious Procedure-Related Adverse Events (Safety)** _(time frame: 30 days)_

## Locations (4)

- Macarthur Urology, Campbelltown, New Southwales, Australia
- Alpha West Mead Private Hospital PTY Limited, Westmead, New Southwales, Australia
- Goldfields Urology, Bendigo, Victoria, Australia
- Austin Health, Heidelberg, Victoria, Australia

## Recent Field Changes (last 30 days)

- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.whyStopped` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `locations.macarthur urology|campbelltown|new southwales|australia` — added _(2026-05-12)_
- `locations.alpha west mead private hospital pty limited|westmead|new southwales|australia` — added _(2026-05-12)_
- `locations.goldfields urology|bendigo|victoria|australia` — added _(2026-05-12)_
- `locations.austin health|heidelberg|victoria|australia` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04771182.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04771182*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*